Metastasis
Loss of TIP30 heightens susceptibility to tumor development
Published in Hepatitis Weekly, February 16th, 2004
"TIP30, also called CC3 or Htatip2, is a putative metastasis suppressor that promotes apoptosis and inhibits angiogenesis. Although TIP30 has several characteristic features of a tumor suppressor in in vitro analyses, tumor development as a result of TIP30 inactivation has not been demonstrated in vivo, and abnormal expression of TIP30 in human cancer has not been reported," according to scientists in the United States.
"Using genetically engineered mice and cells deficient in TIP30, we show that TIP30-deficient mice have a high incidence of hepatocellular carcinoma and other tumors, and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-02-16)
More Articles from Hepatitis Weekly
- Chronic Hepatitis B
Early treatment response foreshadows good outcomes for patients with HBV type C - Gastroenterology
Interferon lowers the risk for liver cancer in patients with chronic hepatitis C - Hemophilia
Treatment for HIV and HCV infections in hemophiliacs reviewed - Hepatitis A Vaccine
Typhoid/hepatitis A vaccine effective as booster dose in primed adults - Hepatitis B Vaccine
HBsAg variants break tolerance in hepatitis B surface antigen mice - Hepatitis C Virus
Chronic hepatitis C patients to benefit from guidance on new drugs and treatments - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
